Answers are grounded in this paper and cite their sources.
Shows that cyclometalated iron(II) complexes induce ferroptosis in gastric cancer cells, suggesting new treatment options.
High Resolution Image Download MS PowerPoint Slide A series of cyclometalated iron(II) complexes of the general formula [Fe II (ĈN)(N̂N) 2 ]PF 6, where HĈN = 2-phenylpyridine (phpyH) or 7,8-benzoquinoline (bzqH) and N̂N = 2,2′-bipyridine (bpy) or 1,10-phenanthroline (phen), has been synthesized by reacting [Fe 2 (CO) 9 ] with the selectively brominated derivatives of phpyH and bzqH, namely, phpyBr or bzqBr, followed by substitution reactions with diimine ligands (bpy or phen). The structures have been confirmed by X-ray diffraction crystallography, NMR, UV–vis spectroscopy, and cyclic voltammetry. Compared to cisplatin and oxaliplatin, complexes 3 (ĈN = phpy/N̂N = phen), 4 ĈN = bzq/N̂N = bpy), and 5 (ĈN = bzq/N̂N = phen) exhibited superior cytotoxicity in two gastric cancer cell lines, and complex 2 (ĈN = phpy/N̂N = bpy) was almost nontoxic on a noncancerous cell line. At the molecular level, the compounds activate ER stress pathway effectors (ATF4 and CHOP) while inhibiting GP x 4 expression, suggesting induction of ferroptosis. This study highlights the broad potential for anticancer applications of new cyclometalated compounds based on earth-abundant iron, which are more affordable and environmentally friendly than their ruthenium and osmium counterparts.
No takes yet. Share an insight, caveat, or question.
Torres-Gutierrez et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: